Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03117738 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease
A Phase 1 study, sponsored by Nature Cell Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03117738 is a Phase 1 study that has completed, run by Nature Cell Co.. The registered enrollment target is 21 participants.
The verdict
NCT03117738, a Phase 1 study, has completed, sponsored by Nature Cell Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1 ratio. AstroStem or placebo control will be administered via I.V. at Week 0. This procedure will be repeated 9 times at 2-week interval. Subjects will be scheduled for two follow-up visits at Weeks 30 and 52 to evaluate primary and secondary outcome endpoints.
Interventions
- DRUG AstroStem
- OTHER Placebo-Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-05-09 |
| Est. Completion | 2019-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03117738
The ClinicalTrials.gov registry entry for NCT03117738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nature Cell Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AstroStem is the first listed.
NCT03117738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03117738 about?
NCT03117738 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease". This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1 ratio. AstroStem or placebo contro...
What is the current status of trial NCT03117738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-05-09. Estimated completion is 2019-08-31.
What interventions are being tested in trial NCT03117738?
The interventions under investigation include: AstroStem (DRUG), Placebo-Control (OTHER).
Who is sponsoring clinical trial NCT03117738?
This trial is sponsored by Nature Cell Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.